What was studied?
This randomized study followed 611 adults without diabetes for 68 weeks. Both groups received intensive behavioral therapy and an initial low-calorie diet.
What did the researchers report?
Semaglutide produced greater average weight reduction than placebo alongside that shared intervention. Gastrointestinal adverse events were also more frequent in the semaglutide group.
What are the limits?
The result concerns the full trial setting, not a stand-alone material. The study does not separate every contribution of dietary support, counseling and drug treatment, and its population limits generalization.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.